Prognostic Significance of CMD Assessed by IMR in HCM Patients

NCT ID: NCT06190704

Last Updated: 2024-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

191 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-13

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions. However, its impact on CMD in the hypertrophic cardiomyopathy (HCM), whether assessed invasively or non-invasively, is yet to be investigated. We assessed the prognostic importance of CMD using less invasive coronary angiography-derived IMR (caIMR) in HCM patients with nonobstructive epicardial coronary arteries.Patients with HCM who underwent invasive coronary angiography for suspected myocardial ischemia were included. Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR\>25U, in line with prior research, and the primary study endpoint was major adverse cardiac events (MACE).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients diagnosed with HCM and referred to the catheterization lab at Shanghai Tenth People's Hospital between 2014 and 2023 for invasive coronary angiography (CAG) due to suspected myocardial ischemia were included in this single-center retrospective observational study. The inclusion criteria of the present study were as follows: 1) Age \>18 years old; 2) echocardiographic evidence of HCM, defined as LV myocardial wall thickness of ≥15 mm and or a LV myocardial wall thickness of ≥13 mm in individuals with a family history of HCM, in the absence of an alternative cause for LV hypertrophy. The exclusion criteria were: 1) significant mitral regurgitation; 2) second and third-degree atrioventricular block; 3) presence of significant epicardial coronary stenosis (≥50% stenosis) on CAG; 4) poor life expectancy resulting from concurrent health disease.; and 5) reduced contrast opacification (for caIMR assessment). Our study was conducted in accordance with the Helsinki Declaration and was approved by the ethical review board of Shanghai Tenth People's Hospital.

The essential clinical data, including age, gender, systolic and diastolic blood pressure, heart rate, as well as the past medical history encompassing diabetes, hypertension, hyperlipidemia, stroke, atrial fibrillation, heart failure, family history of HCM, syncope, and smoking history, were systematically recorded. Additionally, laboratory parameters such as total cholesterol, high- and low-density lipoprotein, triglycerides, and N-terminal pro-brain natriuretic peptide were documented. The cardiovascular medical medications, including beta-blockers, antiplatelet agents, ACE inhibitors/ARBs, calcium channel blockers, anticoagulants, diuretics, and amiodarone, for all participants were also noted. Data from electrocardiography, echocardiography, and coronary angiography were diligently collected.

Echocardiography was conducted using an available digital ultrasound system by two cardiologists who were unaware of the clinical data. Measurements, including M mode, standard two-dimensional (2D), and pulsed Doppler, were carried out by the guidelines set by the American Society of Echocardiography. Cardiac dimensions were determined using the average of three cardiac cycles. Parameters such as LV ejection fraction, septal and left posterior wall thickness, left atrium diameter, LV end-systolic diameter, LV end-diastolic diameter, and LV outflow tract gradient were assessed.

Coronary angiography was performed at the operators' discretion, capturing multiple views at either 15 or 30 frames per second. caIMR was determined using the Flash Angio system, consisting of the Flash Angio console, Flash Angio software, and Flash Pressure transducer from Rainmed Ltd., Suzhou, China. A validated protocol utilizing computational pressure-flow dynamics (CPFD) was applied for caIMR estimation in three sequential steps. Initially, a simulated three-dimensional reconstruction of coronary arteries was generated for the targeted vessels. Subsequently, angio-Fractional Flow Reserve (angio-FFR) was estimated using CPFD, incorporating the estimated hyperemic aortic pressure (P'a) based on mean aortic pressure. The calculation of caIMR was then performed using the provided equation:

In this context, (Pd)hyp represents the mean pressure at the distal position during maximal hyperemia, with L denoting a constant representing the length from the inlet to the distal position. The constant K is assigned a value of 2.1, and Vdiastole stands for the mean flow velocity at the distal position during diastole. Additionally, Vhyp is calculated as K multiplied by Vdiastole, signifying the mean flow velocity at the distal position during maximal hyperemia.

caIMR was assessed in at least one of the three coronary arteries for all patients in our study. The epicardial vessel exhibiting the highest caIMR value among the three major coronary vessels was chosen for analysis. In the present study, CMD was identified based on caIMR\>25U, consistent with observations from prior research Follow-up was conducted over a mean 43-month period through telephone contact or outpatient visits. The primary clinical endpoints in this study encompassed major adverse cardiac events (MACE), which included: 1) cardiac death: defined as events occurring in the context of cardiac decompensation, pulmonary edema, or progression to end-stage disease, along with other cardiac-related deaths; 2) non-cardiac death: defined as any death occurring during the follow-up period, irrespective of the cause; 3) cardiac readmissions: encompassing hospitalizations for heart failure, myocardial infarction, unstable angina, and malignant arrhythmias; and 4) ischemic stroke: denoting a stroke caused by a blockage in the blood flow to the brain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Cicrovascular Dysfunction Hypertrophic Cardiomyopathy Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CMD

Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR\>25U, in line with prior research.

caIMR

Intervention Type DEVICE

Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.

non-CMD

Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR≤25U, in line with prior research.

caIMR

Intervention Type DEVICE

Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

caIMR

Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years old;
* echocardiographic evidence of HCM, defined as LV myocardial wall thickness of ≥15 mm and or a LV myocardial wall thickness of ≥13 mm in individuals with a family history of HCM, in the absence of an alternative cause for LV hypertrophy

Exclusion Criteria

* significant mitral regurgitation;
* second and third-degree atrioventricular block;
* presence of significant epicardial coronary stenosis (≥50% stenosis) on CAG;
* poor life expectancy resulting from concurrent health disease.;
* reduced contrast opacification (for caIMR assessment)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ya-Wei Xu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ya-Wei Xu

Chief Physician

Responsibility Role SPONSOR_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

caIMR-HCM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.